Featured Research

from universities, journals, and other organizations

New pathway for drug development? Targeting alpha arrestins could increase therapeutic benefits of drugs and negate adverse results

Date:
December 10, 2012
Source:
Nationwide Children's Hospital
Summary:
A newly found understanding of receptor signaling may have revealed a better way to design drugs. A study from Nationwide Children's Hospital suggests that a newly identified group of proteins, alpha arrestins, may play a role in cell signaling that is crucial to new drug development. The study appears in PLOS ONE.

A newly found understanding of receptor signaling may have revealed a better way to design drugs. A study from Nationwide Children's Hospital suggests that a newly identified group of proteins, alpha arrestins, may play a role in cell signaling that is crucial to new drug development. The study appears in PLOS ONE.

More than one-third of drugs on the market work by targeting G protein-coupled receptors that control how cells communicate and function. With many hundreds of members, G protein-coupled receptors are the largest family of signaling receptors throughout the body.

Once a cell's G protein-coupled receptor binds with a natural ligand or a drug, intracellular G proteins and beta arrestins independently mediate various signals. Immediately following, beta arrestins block further signaling of G proteins and recruit proteins to remove the receptor to halt cell signaling. Those receptors can subsequently recycle to the cell surface or be destroyed.

"Receptor down regulation caused by beta arrestins can interfere with drug efficacy because the G protein-coupled receptor that the drug has been targeting is absent from the cell surface," said Carlos E. Alvarez, PhD principal investigator in the Center for Molecular and Human Genetics at The Research Institute at Nationwide Children's Hospital and lead study author. "This is why patients who are prescribed long-term medication can become drug-tolerant and require higher and higher doses."

In some cases, a drug's ability to trigger beta arrestin effects and block G protein signaling is preferential. Take beta blockers, for example. As the name suggests, beta blockers interfere with the binding to the receptor for epinephrine and other stress hormones, weakening the hormones' effects and therefore being useful in treating irregular heartbeats, prevention of second heart attacks, hypertension and other conditions. Screening has revealed that the beta blocker Carvedilol may be the most ideal for treatment of heart conditions as it reduces the cardiotoxic effects of G protein signaling, while increasing the cardioprotective effects of beta arrestin signaling.

Yet, it seems that beta arrestins may only be part of the cell signaling story. In 2008, Dr. Alvarez discovered a subfamily of arrestins that his team named alpha arrestins. In the current study, Fortune Shea in Dr. Alvarez's lab used biochemical and imaging approaches to further identify the role alpha arrestins play in cell signaling.

He found that alpha arrestins respond to receptor binding and recruit enzymes that chemically modify the receptor to initiate aspects of down regulation. These effects occur in the first five minutes after the receptor is bound, the same time frame that beta arrestins are known to have roles in triggering down regulation. The team is also the first to find that alpha arrestins function coordinately with beta arrestins.

"Our findings suggest that alpha arrestins, like beta arrestins, are ubiquitous regulators of G-protein coupled receptor signaling," says Dr. Alvarez. "It seems that like beta arrestins, alpha arrestins could have great pharmacological relevance."

A major effort in pharmacology is to develop drugs with functional selectivity that either target G protein or beta arrestin signaling effects. Dr. Alvarez foresees alpha arrestins becoming a big player in the refining of such efforts.

"Just as has been discovered with beta blockers and beta arrestin, I expect we'll find drugs that also have significant alpha arrestin effects," he says. "I believe that targeting alpha arrestins will allow us to develop compounds that are more effective and have reduced side effects," says Dr. Alvarez.


Story Source:

The above story is based on materials provided by Nationwide Children's Hospital. Note: Materials may be edited for content and length.


Journal Reference:

  1. Fortune F. Shea, Jennie L. Rowell, Yechaowei Li, Tien-Hsien Chang, Carlos E. Alvarez. Mammalian Alpha Arrestins Link Activated Seven Transmembrane Receptors to Nedd4 Family E3 Ubiquitin Ligases and Interact with Beta Arrestins. PLoS ONE, 2012; 7 (12): e50557 DOI: 10.1371/journal.pone.0050557

Cite This Page:

Nationwide Children's Hospital. "New pathway for drug development? Targeting alpha arrestins could increase therapeutic benefits of drugs and negate adverse results." ScienceDaily. ScienceDaily, 10 December 2012. <www.sciencedaily.com/releases/2012/12/121210133452.htm>.
Nationwide Children's Hospital. (2012, December 10). New pathway for drug development? Targeting alpha arrestins could increase therapeutic benefits of drugs and negate adverse results. ScienceDaily. Retrieved July 30, 2014 from www.sciencedaily.com/releases/2012/12/121210133452.htm
Nationwide Children's Hospital. "New pathway for drug development? Targeting alpha arrestins could increase therapeutic benefits of drugs and negate adverse results." ScienceDaily. www.sciencedaily.com/releases/2012/12/121210133452.htm (accessed July 30, 2014).

Share This




More Health & Medicine News

Wednesday, July 30, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Generics Eat Into Pfizer's Sales

Generics Eat Into Pfizer's Sales

Reuters - Business Video Online (July 29, 2014) Pfizer, the world's largest drug maker, cut full-year revenue forecasts because generics could cut into sales of its anti-arthritis drug, Celebrex. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
Nigeria Ups Ebola Stakes on 1st Death

Nigeria Ups Ebola Stakes on 1st Death

Reuters - Business Video Online (July 29, 2014) Nigerian authorities have shut and quarantined a Lagos hospital where a Liberian man died of the Ebola virus, the first recorded case of the highly-infectious disease in Africa's most populous economy. David Pollard reports Video provided by Reuters
Powered by NewsLook.com
Running 5 Minutes A Day Might Add Years To Your Life

Running 5 Minutes A Day Might Add Years To Your Life

Newsy (July 29, 2014) According to a new study, just five minutes of running or jogging a day could add years to your life. Video provided by Newsy
Powered by NewsLook.com
Ebola Outbreak Poses Little Threat To U.S.: CDC

Ebola Outbreak Poses Little Threat To U.S.: CDC

Newsy (July 29, 2014) The Ebola outbreak in West Africa poses little threat to Americans, according to officials with the Centers for Disease Control and Prevention. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins